Arcus Biosciences/$RCUS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Arcus Biosciences
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Ticker
$RCUS
Sector
Primary listing
NYSE
Employees
627
Headquarters
Website
RCUS Metrics
BasicAdvanced
$2.1B
-
-$3.39
0.77
-
Price and volume
Market cap
$2.1B
Beta
0.77
52-week high
$22.11
52-week low
$6.50
Average daily volume
1.7M
Financial strength
Current ratio
3.647
Quick ratio
3.596
Long term debt to equity
27.294
Total debt to equity
30.275
Interest coverage (TTM)
-46.88%
Profitability
EBITDA (TTM)
-365
Gross margin (TTM)
-109.58%
Net profit margin (TTM)
-142.08%
Operating margin (TTM)
-156.25%
Effective tax rate (TTM)
-0.29%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-21.06%
Return on equity (TTM)
-68.13%
Valuation
Price to revenue (TTM)
8.1
Price to book
4.74
Price to tangible book (TTM)
4.74
Price to free cash flow (TTM)
-4.19
Free cash flow yield (TTM)
-23.87%
Free cash flow per share (TTM)
-4.609
Growth
Revenue change (TTM)
-8.75%
Earnings per share change (TTM)
7.89%
3-year revenue growth (CAGR)
-17.83%
3-year earnings per share growth (CAGR)
48.27%
What the Analysts think about RCUS
Analyst ratings (Buy, Hold, Sell) for Arcus Biosciences stock.
Bulls say / Bears say
Arcus’s casdatifan achieved a median progression-free survival of 12.2 months in a pooled analysis of 121 heavily pretreated clear cell RCC patients, significantly outperforming Merck’s Welireg benchmark of 5.6–7.3 months and underscoring its differentiated efficacy profile. (Investors.com)
In the Phase 2 EDGE-Gastric study, Arcus’s domvanalimab plus zimberelimab and chemotherapy regimen achieved a median overall survival of 26.7 months in first-line upper GI adenocarcinomas, outperforming standard benchmarks and highlighting potential in a high-unmet-need setting. (Investing.com)
As of March 31, 2025, Arcus reported $1.0 billion in cash, cash equivalents, and marketable securities, providing a robust runway to advance its three lead programs through initial pivotal readouts. (Investing.com)
Gilead returned its license for etrumadenant to Arcus in June 2025 after Arcus decided not to pursue a Phase 3 trial, signaling diminished partner confidence and narrowing of the company’s pipeline. (Fierce Biotech)
Arcus’s net loss widened to $112 million in Q1 2025 from $4 million a year earlier, with operating cash burn surging to $132 million from $2 million, highlighting accelerating cash consumption ahead of key clinical catalysts. (Panabee)
Investor’s Business Daily warned that despite RCUS raising its Relative Strength rating to 85, the stock may need to establish a proper buy point and cautioned investors against chasing shares amid biotech volatility. (Investors.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
RCUS Financial Performance
Revenues and expenses
RCUS Earnings Performance
Company profitability
RCUS News
AllArticlesVideos
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Business Wire1 week ago
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
Business Wire3 weeks ago
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
Business Wire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcus Biosciences stock?
Arcus Biosciences (RCUS) has a market cap of $2.1B as of November 09, 2025.
What is the P/E ratio for Arcus Biosciences stock?
The price to earnings (P/E) ratio for Arcus Biosciences (RCUS) stock is 0 as of November 09, 2025.
Does Arcus Biosciences stock pay dividends?
No, Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders as of November 09, 2025.
When is the next Arcus Biosciences dividend payment date?
Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcus Biosciences?
Arcus Biosciences (RCUS) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.